Developing a new treatment for tuberculosis using MmpL3 inhibitors
Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis
['FUNDING_OTHER'] · TARN BIOSCIENCES, INC. · NIH-10883595
This study is testing a new medication called HC2099 to help treat tuberculosis, especially the tougher drug-resistant types, by targeting a key protein that the TB bacteria need to survive, with the hope of making treatment easier and more effective for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TARN BIOSCIENCES, INC. (nih funded) |
| Locations | 1 site (EAST LANSING, UNITED STATES) |
| Trial ID | NIH-10883595 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a new medication, HC2099, to treat tuberculosis (TB), including drug-resistant forms. The approach involves targeting a specific protein, MmpL3, which is crucial for the survival of the TB bacteria. By inhibiting this protein, the researchers aim to develop a treatment that is more effective and has fewer side effects than current therapies, which often require long courses of multiple medications. This could improve patient adherence to treatment and help combat the rise of drug-resistant TB.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with drug-susceptible or multidrug-resistant tuberculosis.
Not a fit: Patients with other types of infections or those who do not have tuberculosis will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and easier-to-follow treatment for tuberculosis, potentially saving lives and reducing the spread of drug-resistant strains.
How similar studies have performed: Previous research has shown promise in targeting MmpL3 as a viable approach to treating tuberculosis, indicating that this strategy has potential based on earlier findings.
Where this research is happening
EAST LANSING, UNITED STATES
- TARN BIOSCIENCES, INC. — EAST LANSING, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VRBANAC, JOHN JAMES — TARN BIOSCIENCES, INC.
- Study coordinator: VRBANAC, JOHN JAMES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.